Cyclodextrins as carriers
January 18, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3453257 Chemiluminescent phthalhydrazide-labeled hapten conjugates Water-soluble steroid compounds Inclusion compound of lankacidin-group antibiotic and use thereof Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes Pharmaceutical preparations containing cyclodextrin derivatives Cyclodextrin adsorbing-material Controlled release pharmaceutical composition Derivatives of γ-cylodextrin Administration of steroid hormones InventorAssigneeApplicationNo. 298634 filed on 01/18/1989US Classes:424/178.1, CONJUGATE OR COMPLEX OF MONOCLONAL OR POLYCLONAL ANTIBODY, IMMUNOGLOBULIN, OR FRAGMENT THEREOF WITH NONIMMUNOGLOBULIN MATERIAL424/1.37, Radionuclide or intended radionuclide in an organic compound424/94.1, ENZYME OR COENZYME CONTAINING436/56, TRACERS OR TAGS436/57, INCLUDING USE OF RADIOACTIVE PROPERTIES436/86, PEPTIDE, PROTEIN OR AMINO ACID436/544, Producing labeled antigens514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/58, Dextrin or derivative514/777, Carbohydrate or lignin, or derivative514/778Starch or derivativeExaminersPrimary: Griffin, Ronald W.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/70C08B 037/16 G01N 033/533 AbstractCyclodextrins can be coupled to biorecognition molecules such as antibodies. The cyclodextrins so coupled provide a cavity or complexation zone into which active agents such as labels, drugs and the like may be incorporated. The active agent forms a noncovalently bonded inclusion complex within the cavity of the cyclodextrin. It remains associated with the cyclodextrin and the coupled biorecognition molecule and thus can be delivered to the other half of the biospecific recognition pair. A process for producing these materials is also disclosed. The process includes the steps of activating a primary hydroxyl site on a cyclodextrin; linking a biorecognition molecule to the activated primary hydroxyl site on the cyclodextrin in either a direct covalent linkage or through a covalently linked spacer; and introducing a guest molecule (active agent) into the cavity of the derivatized cyclodextrin to form an inclusion complex.Other References
|
| ||||||||||||||
